TW201329105A - Human Notch1 decoys - Google Patents

Human Notch1 decoys Download PDF

Info

Publication number
TW201329105A
TW201329105A TW101135396A TW101135396A TW201329105A TW 201329105 A TW201329105 A TW 201329105A TW 101135396 A TW101135396 A TW 101135396A TW 101135396 A TW101135396 A TW 101135396A TW 201329105 A TW201329105 A TW 201329105A
Authority
TW
Taiwan
Prior art keywords
egf
repeat
amino acid
fusion proteins
human notch1
Prior art date
Application number
TW101135396A
Inventor
Jan Kitajewski
Original Assignee
Thr Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161543186P priority Critical
Application filed by Thr Trustees Of Columbia University In The City Of New York filed Critical Thr Trustees Of Columbia University In The City Of New York
Publication of TW201329105A publication Critical patent/TW201329105A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Abstract

Provided herein are Notch1 fusion proteins. These fusion proteins contain an extracellular domain of a human Notch1 receptor protein and an Fc portion of an antibody bound thereto. The extracellular domain (ECD) of the human Notch1 receptor protein commences with an amino acid present at the N-terminus of EGF like repeat 10 and extends at least through a C-terminal amino acid of EGF like repeat 23. The N-terminal portion of the ECD of the human Notch1 receptor protein may extend to a C-terminal amino acid of EGF like repeat 24 or may extend to a C-terminal amino acid of EGF like repeat 36. Compositions of these fusion proteins are also provided. Also provided are methods of treating age-related macular degeneration (AMD), diabetic retinopathy and cancer using the fusion proteins described herein.
TW101135396A 2011-10-04 2012-09-26 Human Notch1 decoys TW201329105A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201161543186P true 2011-10-04 2011-10-04

Publications (1)

Publication Number Publication Date
TW201329105A true TW201329105A (en) 2013-07-16

Family

ID=48044136

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101135396A TW201329105A (en) 2011-10-04 2012-09-26 Human Notch1 decoys

Country Status (19)

Country Link
US (2) US9738708B2 (en)
EP (1) EP2763700A4 (en)
JP (1) JP2014532061A (en)
KR (1) KR20140093942A (en)
CN (1) CN103917247A (en)
AR (1) AR088048A1 (en)
AU (1) AU2012318664A1 (en)
BR (1) BR112014008025A2 (en)
CA (1) CA2850944A1 (en)
CL (1) CL2014000852A1 (en)
HK (1) HK1198427A1 (en)
IL (1) IL231920D0 (en)
MX (1) MX2014004132A (en)
PE (1) PE14792014A1 (en)
RU (1) RU2014117160A (en)
SG (1) SG11201401186RA (en)
TW (1) TW201329105A (en)
WO (1) WO2013052607A1 (en)
ZA (1) ZA201403044B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
WO2009025867A2 (en) 2007-08-23 2009-02-26 The Trustees Of Columbia University In The City Of New York Compositions of humanized notch fusion proteins and methods of treatment
MX2011001805A (en) 2008-08-22 2011-09-30 Univ Columbia Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling.
TW201329105A (en) * 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York Human Notch1 decoys
CN105585636A (en) * 2015-11-24 2016-05-18 南方医科大学 Human NOTCH1 NICD protein Ser2162 locus phosphorylation antibody and preparation method and application thereof
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE20030751A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta, binding domains in toporythmic proteins, and methods based thereon
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (en) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene involved in CADASIL, diagnostic method and therapeutic application
US6379925B1 (en) * 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
AU2003226537A1 (en) 2002-04-05 2003-10-27 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
EP1525221A1 (en) 2002-08-03 2005-04-27 Lorantis Limited Conjugate of notch signalling pathway modulators and their use in medical treatment
EP1537145A1 (en) 2002-09-10 2005-06-08 Lorantis Limited Pharmaceutical compositions and medical treatments comprising notch ligand proteins
WO2003042246A2 (en) 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
WO2006047878A1 (en) 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
WO2007016419A2 (en) 2005-07-29 2007-02-08 The General Hospital Corporation Methods and compositions for reducing skin damage
RU2461569C2 (en) 2006-10-19 2012-09-20 Дженентек, Инк. Agonist notch3 antibodies and application thereof for treating notch3-associated diseases
US8088617B2 (en) * 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
WO2009025867A2 (en) * 2007-08-23 2009-02-26 The Trustees Of Columbia University In The City Of New York Compositions of humanized notch fusion proteins and methods of treatment
DK2307459T3 (en) * 2008-07-08 2015-02-09 Oncomed Pharm Inc Notch1 receptor binding agents, and methods of use thereof
MX2011001805A (en) 2008-08-22 2011-09-30 Univ Columbia Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling.
TW201329105A (en) * 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York Human Notch1 decoys

Also Published As

Publication number Publication date
ZA201403044B (en) 2016-01-27
HK1198427A1 (en) 2015-04-24
WO2013052607A9 (en) 2014-04-10
JP2014532061A (en) 2014-12-04
MX2014004132A (en) 2014-07-24
US9738708B2 (en) 2017-08-22
US10227399B2 (en) 2019-03-12
US20140271643A1 (en) 2014-09-18
EP2763700A1 (en) 2014-08-13
RU2014117160A (en) 2015-11-10
EP2763700A4 (en) 2015-05-27
AR088048A1 (en) 2014-05-07
WO2013052607A1 (en) 2013-04-11
BR112014008025A2 (en) 2017-04-11
KR20140093942A (en) 2014-07-29
CL2014000852A1 (en) 2014-12-12
US20170306006A1 (en) 2017-10-26
CA2850944A1 (en) 2013-04-11
PE14792014A1 (en) 2014-11-05
IL231920D0 (en) 2014-05-28
AU2012318664A1 (en) 2014-05-22
CN103917247A (en) 2014-07-09
SG11201401186RA (en) 2014-04-28

Similar Documents

Publication Publication Date Title
CA2820681C (en) Use of chimeric antigen receptor-modified t cells to treat cancer
JO3182B1 (en) High Affinity Human Antibodies to Human Angiopoietin-2
AU2017203511B2 (en) T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
NZ602220A (en) Antibodies with ph dependent antigen binding
MX2012006406A (en) Multispecific antibodies, antibody analogs, compositions, and methods.
MX344727B (en) IMPROVED HIGH CONCENTRATION ANTI-TNFa ANTIBODY LIQUID FORMULATIONS.
UA94899C2 (en) Fixed dosing of her antibodies
MX2009012343A (en) Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto.
TW201406784A (en) Optimization of antibodies that bind lymphocyte activation gene-3(LAG-3), and uses thereof
GB201112429D0 (en) Antigen-binding proteins with increased FcRn binding
SG173688A1 (en) Specific binding proteins and uses thereof
CY1116195T1 (en) FACTORS BINDING notch 1 receptor and these METHODS OF USE
WO2015142675A8 (en) Treatment of cancer using chimeric antigen receptor
WO2008121615A3 (en) Antibody formulation
EA201170475A1 (en) Immunotherapy medicines against tcr complex
AU2019204841A1 (en) Novel heterodimeric proteins
TW201602344A (en) Antibody constant region variant
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2011160119A8 (en) Anti-gd2 antibodies
TW201801743A (en) Low affinity blood brain barrier receptor antibodies and uses therefor
MY149630A (en) Antibodies against amyloid-beta peptide
MX2011003183A (en) Frizzled-binding agents and uses thereof.
EA201290570A1 (en) Constructions connecting with ron and methods of their use
WO2011110642A3 (en) Monoclonal antibodies against c-met
EA201370154A1 (en) Therapy on the basis of ligands of chemosensor receptors